Nav: Home

Research paves way for new source for leukemia drug

March 20, 2019

CORVALLIS, Ore. - Chemistry researchers at Oregon State University have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

The synthesis of cephalotaxine and homoharringtonine (HHT) paves the way toward less-expensive, more readily available leukemia drugs whose production is not subject to the risks and inefficiencies associated with harvesting natural sources.

Also, the synthesis of cephalotaxine opens the door to preparing other, structurally related compounds for evaluation as potential new cancer drugs.

"We want to partner with industry so we don't have to grow trees to get this anymore," said corresponding author Christopher Beaudry, associate professor of chemistry in OSU's College of Science. "And maybe we can come up with a more potent protein translation inhibitor, or a more selective inhibitor. There's also a chance this molecule can find application in blocking bacterial protein synthesis, which would be useful for treating antibiotic-resistant pathogens."

Findings were published in Angewandte Chemie.

HHT, also known as Synribo or omacetaxine mepesuccinate, is used to treat chronic myeloid leukemia, one of four main types of the disease.

Historically, HHT has been made by adding an ester to cephalotaxine, an alkaloid derived from the leaves of an Asian tree: the plum yew. And the only way to get more cephalotaxine was to plant more plum yews.

That's problematic, Beaudry said.

"Trees don't grow very fast," he said. "And any kind of agricultural problem can affect production of the material. By using chemical synthesis, we can start with commodity chemicals to prepare cephalotaxine, and we will further optimize the process to make it commercially viable."

Leukemia is a type of cancer that originates in the blood-forming cells of the bone marrow. Nearly 200,000 people in the U.S. are diagnosed with leukemia each year.

Myeloid leukemias, which are also called myelocytic, myelogenous or non-lymphocytic leukemias, start in early myeloid cells. Myeloid cells are what eventually become platelet-making cells and white blood cells other than lymphocytes.

Chronic myeloid leukemia develops slowly, and most patients can live with it for several years, but it's harder to cure than the acute form of the disease. It's characterized by a chromosome abnormality that results in a protein overproduction, leading to the proliferation of the cancer cells.

Chronic myeloid leukemia is treated with drugs, such as Gleevec, that bind to a cancer-causing protein and inactivate it - until the cancer mutates and the drug doesn't work anymore, which is where HHT comes in. HHT shuts off production of all proteins that the fast-growing leukemia cells require.

In addition, HHT holds promise for thwarting chronic myeloid leukemia stem cells, as well as for combating other cancer cell lines.

Beaudry and graduate student Xuan Ju used an oxidative ring-opening of a furan, a type of organic compound, to trigger the HHT synthesis via a reaction known as a spontaneous transannular Mannich cyclization.

"From start to finish - all nine steps from the chemical we buy - the yield is greater than 5 percent, which sounds terrible but is actually quite good," Beaudry said. "Typically the yield for any process would be much lower - think about how much tree mass is required to make HHT - and we think we can make further improvements as well."
-end-
The National Science Foundation and OSU supported this research.

Oregon State University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".